Analysts think RDHL stock price could increase by 188927%
Jun 14, 2024, 6:28 AM
-9.27%
What does RDHL do
RedHill Biopharma Ltd. specializes in developing medications for gastrointestinal and infectious diseases, notably promoting Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage clinical programs include treatments like RHB-204 for NTM disease and opaganib for multiple indications, alongside RHB-107 for COVID-19 and other diseases.
3 analysts think RDHL stock price will increase by 188927.07%. The current median analyst target is $775.20 compared to a current stock price of $0.41. The lowest analysts target is $767.60 and the highest analyst target is $798.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
